| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |